Healthcare services company Agilon Health (NYSE: AGL) will be announcing earnings results this Tuesday after the bell. Here’s what to look for.
agilon health beat analysts’ revenue expectations by 1.8% last quarter, reporting revenues of $1.53 billion, down 4.5% year on year. It was a slower quarter for the company, with a significant miss of analysts’ EPS estimates and EBITDA guidance for next quarter missing analysts’ expectations significantly. It lost -36,000 customers and ended up with a total of 491,000.
Is agilon health a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting agilon health’s revenue to be flat year on year at $1.47 billion, slowing from the 38.7% increase it recorded in the same quarter last year. Adjusted loss is expected to come in at -$0.11 per share.
The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. agilon health has missed Wall Street’s revenue estimates five times over the last two years.
Looking at agilon health’s peers in the healthcare providers & services segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Select Medical delivered year-on-year revenue growth of 4.5%, meeting analysts’ expectations, and CVS Health reported revenues up 8.4%, topping estimates by 5.1%. Select Medical traded down 15.1% following the results while CVS Health’s stock price was unchanged.
Read our full analysis of Select Medical’s results here and CVS Health’s results here.
Debates around the economy’s health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the healthcare providers & services stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.3% on average over the last month. agilon health is down 25.8% during the same time and is heading into earnings with an average analyst price target of $3.59 (compared to the current share price of $1.73).
When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
